AstraZeneca PLC - Asset Resilience Ratio

Latest as of September 2025: 0.03%

AstraZeneca PLC (ZEGA) has an Asset Resilience Ratio of 0.03% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€39.00 Million
≈ $45.60 Million USD Cash + Short-term Investments

Total Assets

€114.46 Billion
≈ $133.81 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how AstraZeneca PLC's Asset Resilience Ratio has changed over time. Check ZEGA PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down AstraZeneca PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is AstraZeneca PLC worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €39.00 Million 0.03%
Total Liquid Assets €39.00 Million 0.03%

Asset Resilience Insights

  • Limited Liquidity: AstraZeneca PLC maintains only 0.03% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

AstraZeneca PLC Industry Peers by Asset Resilience Ratio

Compare AstraZeneca PLC's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biogen Inc
NASDAQ:BIIB
Drug Manufacturers - General 2.74%
Pfizer Inc
SA:PFIZ34
Drug Manufacturers - General 5.48%
AstraZeneca PLC
NYSE:AZN
Drug Manufacturers - General 0.10%
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
Drug Manufacturers - General 17.40%
Aurora Optoelectronics Co Ltd
SHG:600666
Drug Manufacturers - General 5.89%
NanJing Pharmaceutical Co Ltd
SHG:600713
Drug Manufacturers - General 0.85%
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
Drug Manufacturers - General 7.83%
Firebrick Pharma Ltd
AU:FRE
Drug Manufacturers - General 0.29%

Annual Asset Resilience Ratio for AstraZeneca PLC (2014–2024)

The table below shows the annual Asset Resilience Ratio data for AstraZeneca PLC.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.16% €166.00 Million
≈ $194.07 Million
€104.03 Billion
≈ $121.63 Billion
+0.14pp
2023-12-31 0.02% €20.00 Million
≈ $23.38 Million
€101.12 Billion
≈ $118.22 Billion
-0.23pp
2022-12-31 0.25% €239.00 Million
≈ $279.42 Million
€96.48 Billion
≈ $112.80 Billion
+0.18pp
2021-12-31 0.07% €69.00 Million
≈ $80.67 Million
€105.36 Billion
≈ $123.18 Billion
-0.17pp
2020-12-31 0.24% €160.00 Million
≈ $187.06 Million
€66.73 Billion
≈ $78.01 Billion
-1.08pp
2019-12-31 1.32% €811.00 Million
≈ $948.14 Million
€61.38 Billion
≈ $71.76 Billion
-0.01pp
2018-12-31 1.33% €809.00 Million
≈ $945.81 Million
€60.65 Billion
≈ $70.91 Billion
-0.61pp
2017-12-31 1.94% €1.23 Billion
≈ $1.44 Billion
€63.35 Billion
≈ $74.07 Billion
+0.53pp
2016-12-31 1.41% €884.00 Million
≈ $1.03 Billion
€62.53 Billion
≈ $73.10 Billion
+0.39pp
2015-12-31 1.02% €613.00 Million
≈ $716.66 Million
€60.06 Billion
≈ $70.21 Billion
+0.99pp
2014-12-31 0.03% €20.00 Million
≈ $23.38 Million
€58.59 Billion
≈ $68.50 Billion
--
pp = percentage points

About AstraZeneca PLC

F:ZEGA Germany Drug Manufacturers - General
Market Cap
$273.68 Billion
€234.09 Billion EUR
Market Cap Rank
#71 Global
#5 in Germany
Share Price
€75.50
Change (1 day)
-3.82%
52-Week Range
€62.50 - €82.50
All Time High
€82.50
About

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more